Piper Sandler Maintains Overweight on Context Therapeutics, Raises Price Target to $7

Piper Sandler analyst Biren Amin has maintained an Overweight rating on Context Therapeutics (NASDAQ: CNTX) and increased the price target from $4 to $7. This adjustment reflects a positive outlook for the company's performance.